BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor

[Image: see text] Despite advances in the treatment of heart failure in recent years, options for patients are still limited and the disease is associated with considerable morbidity and mortality. Modulating cyclic guanosine monophosphate levels within the natriuretic peptide signaling pathway by i...

Descripción completa

Detalles Bibliográficos
Autores principales: Meibom, Daniel, Micus, Sina, Andreevski, Anna Lena, Anlauf, Sonja, Bogner, Pamela, von Buehler, Clemens-Jeremias, Dieskau, André P., Dreher, Jan, Eitner, Frank, Fliegner, Daniela, Follmann, Markus, Gericke, Kersten Matthias, Maassen, Stefanie, Meyer, Jutta, Schlemmer, Karl-Heinz, Steuber, Holger, Tersteegen, Adrian, Wunder, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791655/
https://www.ncbi.nlm.nih.gov/pubmed/36475653
http://dx.doi.org/10.1021/acs.jmedchem.2c01267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791655/
https://www.ncbi.nlm.nih.gov/pubmed/36475653
http://dx.doi.org/10.1021/acs.jmedchem.2c01267

Ejemplares similares